Condition: Glioma of Spinal Cord · Glioma of Brainstem · Sponsor: Stanford University
The primary purpose of this study is to test whether CAR T cells targeting GD2 (GD2CART) can be successfully made and safely given to children and adults with H3K27M-mutant diffuse midline glioma (DMG). Eligible subjects may have DMG arising in the pons (called difuse intrinisic pontine glioma, DIPG), the spinal cord, or other areas of the brain such as a thalamus
This description comes directly from the study's public registry record.
Ashley Jacobs, RN, BSN · 650-497-7533 · gd2cart@stanfordchildrens.org
Monica Reddy · (650) 736-2690 · secure-sci-cto-neuro-crcs-nio@lists.stanford.edu
Always discuss trial participation with your own doctor first.
| Lucile Packard Children's Hospital (LPCH) | Stanford, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04196413